This was a non-interventional, retrospective, cross-sectional, descriptive study, conducted on the National Health Data System (Système National des Données de Santé, SNDS). The study did not modify the doctor-patient relationship, nor the management or follow-up of patients. Patients with dispensation of canakinumab for gouty arthritis were selected over the period from 08 April 2018 to 07 April 2020; index date was defined as date of the first dispensation of canakinumab in community pharmacy during study period. Patients were described at index date. Medical history and comorbidities, and previous treatments for gouty arthritis were assessed during 3 years prior to index date. Co-treatments of interest for which standard treatments for gouty arthritis were contraindicated or required precautions for use were assessed during 6 months prior to index date.
Study Type
OBSERVATIONAL
Enrollment
15
Novartis
Paris, France
Number of patients treated with canakinumab in France for the treatment of gouty arthritis
Time frame: 2 years
Mean age of patients
Time frame: 3 years
Number of male patients
Time frame: 3 years
Geographic location of patients
Time frame: 3 years
Number of patients with previous treatments for gouty arthritis
Time frame: 3 years
Medical history of patients
Time frame: 3 years
Number of patients with comorbidities
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.